Form 8-K - Current report:
SEC Accession No. 0001140361-26-006176
Filing Date
2026-02-19
Accepted
2026-02-19 16:02:24
Documents
15
Period of Report
2026-02-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20066083_form8k.htm   iXBRL 8-K 45185
2 EXHIBIT 3.1 ef20066083_ex3-1.htm EX-3.1 91055
3 EXHIBIT 10.1 ef20066083_ex10-1.htm EX-10.1 302693
4 EXHIBIT 10.2 ef20066083_ex10-2.htm EX-10.2 143973
  Complete submission text file 0001140361-26-006176.txt   829459

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ird-20260213.xsd EX-101.SCH 3860
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20260213_lab.xml EX-101.LAB 22692
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20260213_pre.xml EX-101.PRE 16550
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20066083_form8k_htm.xml XML 4377
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 26654225
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)